Litcius/Paper detail

Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial

Luke, Jason J, Rutkowski, Piotr, Queirolo, Paola, Del Vecchio, Michele, et al, Dummer, Reinhard

2022Open MIND443 citations

Topics & Concepts

MedicinePembrolizumabClinical endpointPlaceboInterim analysisPopulationInternal medicineMelanomaSurgeryAdjuvant therapyStage (stratigraphy)Clinical trialCancerPathologyCancer researchAlternative medicineImmunotherapyBiologyPaleontologyEnvironmental healthCutaneous Melanoma Detection and ManagementCancer Immunotherapy and BiomarkersCAR-T cell therapy research
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial | Litcius